Shares of Urogen Pharma (NASDAQ:URGN) have been given an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Brokerages have set a twelve-month consensus target price of $31.33 for the company and are expecting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given Urogen Pharma an industry rank of 155 out of 265 based on the ratings given to related companies.

URGN has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Jefferies Group LLC increased their price target on shares of Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a report on Monday.

Urogen Pharma (NASDAQ:URGN) traded up 0.50% during trading on Friday, reaching $29.95. The company’s stock had a trading volume of 11,218 shares. The firm’s market cap is $389.65 million. Urogen Pharma has a one year low of $13.01 and a one year high of $33.77. The company has a 50-day moving average of $27.24 and a 200 day moving average of $20.66.

Several large investors have recently bought and sold shares of URGN. Alps Advisors Inc. purchased a new stake in shares of Urogen Pharma during the second quarter valued at approximately $195,000. LLBH Private Wealth Management LLC purchased a new stake in shares of Urogen Pharma during the second quarter valued at approximately $695,000. Spark Investment Management LLC purchased a new stake in shares of Urogen Pharma during the second quarter valued at approximately $856,000. Menora Mivtachim Holdings LTD. purchased a new stake in shares of Urogen Pharma during the second quarter valued at approximately $2,331,000. Finally, Wildcat Capital Management LLC purchased a new stake in shares of Urogen Pharma during the second quarter valued at approximately $2,439,000. Hedge funds and other institutional investors own 36.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://theolympiareport.com/2017/10/10/zacks-urogen-pharma-urgn-receives-average-recommendation-of-strong-buy-from-brokerages.html.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.